iShares Biotechnology ETF
863 hedge funds and large institutions have $7.66B invested in iShares Biotechnology ETF in 2021 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 280 increasing their positions, 257 reducing their positions, and 70 closing their positions.
63% more funds holding in top 10
Funds holding in top 10: 8 → 13 (+5)
39% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 70
2% more funds holding
Funds holding: 845 → 863 (+18)
9% more repeat investments, than reductions
Existing positions increased: 280 | Existing positions reduced: 257
0% less capital invested
Capital invested by funds: $7.67B → $7.66B (-$7.57M)
2% less call options, than puts
Call options by funds: $498M | Put options by funds: $510M
5.9% less ownership
Funds ownership: 76.67% → 70.77% (-5.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$77.5M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$77M |
| 3 |
TIM
Total Investment Management
Scottsdale,
Arizona
|
+$50.9M |
| 4 |
Twin Tree Management
Dallas,
Texas
|
+$49.2M |
| 5 |
Millennium Management
New York
|
+$41.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$415M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$200M |
| 3 |
Goldman Sachs
New York
|
-$197M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$154M |
| 5 |
JP Morgan Chase
New York
|
-$98M |
IBB Hedge Fund Activity: Q2 2021 in Review
863 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2021, worth a combined $7.66B — down 0.1% from $7.67B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new IBB positions and 70 closed out — a net gain of 27 holders — while 280 added to existing stakes and 257 trimmed.
The largest buyer was Ergoteles, adding an estimated $77.5M. The largest seller was Morgan Stanley, cutting an estimated $415M.
- 863 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2021, up from 845 in Q1 2021.
- Funds reported $7.66B of iShares Biotechnology ETF stock for Q2 2021, down 0.1% quarter-over-quarter.
- 97 funds opened new iShares Biotechnology ETF positions in Q2 2021 and 70 closed out, a net change of +27 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2021 was Ergoteles, an estimated $77.5M added.
- The largest iShares Biotechnology ETF seller in Q2 2021 was Morgan Stanley, an estimated $415M sold.
Based on aggregated 13F filings for Q2 2021.